Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
Solid Biosciences’ muscular dystrophy gene therapy fails to hit the company’s own target, let alone a benchmark set by Sarepta.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?